Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials

Affiliations

¹ Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
² Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island. Electronic address: Michael_A_liu@brown.edu.

Free article

Comment

Quynh-Lan Dao et al. J Thorac Oncol. 2021 Oct.

Free article

. 2021 Oct;16(10):e86-e87.

doi: 10.1016/j.jtho.2021.07.014.

¹ Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
² Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island. Electronic address: Michael_A_liu@brown.edu.

No abstract available

Comment in

Response to "Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials".
Zhao H, Li J, Zhang Z, Zhang L, Zhou X. Zhao H, et al. J Thorac Oncol. 2021 Oct;16(10):e87-e88. doi: 10.1016/j.jtho.2021.08.001. J Thorac Oncol. 2021. PMID: 34561044 No abstract available.

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z, Cui J, Miao L, Zhang L, Yuan X, Fang Y, Fu X, Hu C, Zhu X, Fan Y, Yu Q, Wu G, Jiang O, Du X, Liu J, Gu W, Hou Z, Wang Q, Zheng R, Zhou X, Zhang L. Zhao H, et al. J Thorac Oncol. 2021 Sep;16(9):1533-1546. doi: 10.1016/j.jtho.2021.05.006. Epub 2021 May 24. J Thorac Oncol. 2021. PMID: 34033974 Clinical Trial.